DUBLIN--(BUSINESS WIRE)--The "Vaso-occlusive crisis-associated with sickle cell disease - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
The "Vaso-occlusive-crisis-associated-with-sickle-cell-disease - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vaso-occlusive-crisis-associated-with-sickle-cell-disease pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Vaso-occlusive-crisis-associated-with-sickle-cell-disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vaso-occlusive-crisis-associated-with-sickle-cell-disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Vaso-occlusive-crisis-associated-with-sickle-cell-disease Emerging Drugs Chapters
This segment of the Vaso-occlusive-crisis-associated-with-sickle-cell-disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vaso-occlusive-crisis-associated-with-sickle-cell-disease Emerging Drugs
Inclacumab: Global Blood Therapeutics
Global Blood Therapeutics (GBT) is developing inclacumab - a novel, fully human monoclonal antibody P-selectin inhibitor - for SCD patients with frequent pain crises, also known as vaso-occlusive crises (VOCs). P-selectin inhibition is clinically validated to reduce VOCs, a complication of SCD. GBT has an exclusive worldwide licensing agreement with Roche for inclacumab, which has established pharmacokinetic data, safety and tolerability in more than 500 patients. We have initiated two pivotal Phase 3 studies evaluating the effect of inclacumab on reducing the frequency of VOCs and on hospital readmissions for people with SCD. The THRIVE (Therapy for Reduction with Inclacumab of VOC Episodes) Studies are currently recruiting.
L-citrulline: Asklepion Pharmaceuticals
Intravenous L-citrulline, a non-essential amino acid is being developed by Asklepion, under a license from Vanderbilt University. Researchers at Vanderbilt University found that cardiopulmonary bypass significantly decreased blood levels of citrulline, which compromised the ability to make an important blood vessel dilator, nitric oxide, during surgery and in the postoperative period. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Acute Vaso Occlusive Crisis (VOC).
Key Questions
- How many companies are developing Vaso-occlusive-crisis-associated-with-sickle-cell-disease drugs?
- How many Vaso-occlusive-crisis-associated-with-sickle-cell-disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vaso-occlusive-crisis-associated-with-sickle-cell-disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vaso-occlusive-crisis-associated-with-sickle-cell-disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vaso-occlusive-crisis-associated-with-sickle-cell-disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Global Blood Therapeutics
- Asklepion Pharmaceuticals, LLC
- Prolong Pharmaceuticals
- CSL Behring
- GlycoMimetics
- Hillhurst Pharmaceuticals
Key Products
- Inclacumab
- L-citrulline
- SANGUINATE
- CSL889
- GMI-1687
- HBI 002
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/tdvmy6
